The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
Investors punish the liquid biopsy maker for lacklustre data on its colorectal cancer screen.
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
The nightmare on the public markets is not confined to the bigger groups.
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.